Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA(R) (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival

Randomized, placebo-controlled study confirms ramucirumab, in combination with docetaxel, significantly extended progression-free survival (PFS) in previously treated patients with locally advanced or unresectable or metastatic urothelial carcinoma INDI... Biopharmaceuticals, Oncology Eli Lilly, CYRAMZA, ramucirumab, urothelial carcinoma, bladder cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news